UNITED STA IES PA IENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`15/170,284
`
`ISSUE DATE
`
`01/02/2018
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`9855302
`
`UCHI-34458/US-3/ORD
`
`8885
`
`72960
`7590
`Casimir Jones, S.C.
`2275 DEMING WAY, SUITE 310
`MIDDLETON, WI 53562
`
`12/13/2017
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`Thomas F. Gajewski, Chicago, IL;
`The University of Chicago, Chicago, IL;
`Ayelet Sivan, Chicago, IL;
`Leticia Corrales, Chicago, IL;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`Genome Ex. 1014
`Page 1 of 1502
`
`

`

`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`15/170,284
`
`06/01/2016
`
`Thomas F. Gajewski
`
`UCHI-34458/US-3/ORD
`
`8885
`
`72960
`7590
`Casimir Jones, S.C.
`2275 DEMING WAY, SUITE 310
`MIDDLETON, WI 53562
`
`11/22/2017
`
`EXAMINER
`
`HINES, JANA A
`
`ART UNIT
`
`PAPER NUMBER
`
`1645
`
`NOTIFICATION DATE
`
`DELIVERY MODE
`
`11/22/2017
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the
`following e-mail address(es):
`docketing@casimiriones.com
`Mo.correspondence@casimirjones.com
`
`PTOL-90A (Rev. 04/07)
`
`Genome Ex. 1014
`Page 2 of 1502
`
`

`

`Notice of Allowability
`
`Application No.
`15/170,284
`Examiner
`JA-NA A HINES
`
`Applicant(s)
`Gajewski et al.
`Art Unit
`AIA Status
`1645
`Yes
`
`— The MAILING DATE of this communication appears on the cover sheet with the correspondence address—
`All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included
`herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS
`NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative
`of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.
`
`1.2 This communication is responsive to November 14, 2017 .
`0 A declaration(s)/affidavit(s) under 37 CFR 1.130(b) was/were filed on
`
`2.0 An election was made by the applicant in response to a restriction requirement set forth during the interview on
`restriction requirement and election have been incorporated into this action.
`
`; the
`
`30 The allowed claim(s) is/are 1-26 and 28-30 . As a result of the allowed claim(s), you may be eligible to benefit from the Patent
`Prosecution Highway program at a participating intellectual property office for the corresponding application. For more information
`, please see http://www.uspto.goWpatents/init_eventsipph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
`
`4.0 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
`Certified copies:
`a) 0 All
`*c) 0 None of the:
`b) 0 Some
`1. 0 Certified copies of the priority documents have been received.
`2. 0 Certified copies of the priority documents have been received in Application No.
`3. 0 Copies of the certified copies of the priority documents have been received in this national stage application from the
`International Bureau (PCT Rule 17.2(a)).
`
`" Certified copies not received:
`
`Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file areply complying with the requirements
`noted below. Failure to timely comply will result in ABANDONMENT of this application.
`THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
`
`5.0 CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
`0 including changes required by the attached Examiner's Amendment / Comment or in the Office action of
`Paper No./Mail Date
`Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each
`sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
`
`6.0 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
`attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
`
`Attachment(s)
`1.0 Notice of References Cited (PTO-892)
`2.0 Information Disclosure Statements (PTO/SB/08),
`Paper No./Mail Date
`3.0 Examiner's Comment Regarding Requirement for Deposit
`of Biological Material
`4.2 Interview Summary (PTO-413),
`Paper No./Mail Date. 11/14/17 .
`/JANA A HINES/
`Primary Examiner, Art Unit 1645
`
`5. 2 Examiner's Amendment/Comment
`6. 0 Examiner's Statement of Reasons for Allowance
`7. 0 Other
`
`U.S. Patent and Trademark Office
`PTOL-37 (Rev. 08-13)
`
`Notice of Allowability
`
`Part of Paper No./Mail Date 20171114
`
`Genome Ex. 1014
`Page 3 of 1502
`
`

`

`UNITED STATES DEPARTMENT OF COMMERCE
`U.S. Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`
`APPLICATION NO./
`CONTROL NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR/
`PATENT IN REEXAMINATION
`
`15/170,284
`
`06/01/2016
`
`Gajewski et al.
`
`ATTORNEY DOCKET NO.
`
`UCHI-34458/US-31
`ORD
`
`Casimir Jones, S.C.
`2275 DEMING WAY, SUITE 310
`MIDDLETON, WI 53562
`
`EXAMINER
`
`JA-NA A HINES
`PAPER
`
`ART UNIT
`
`1645
`
`20171114
`
`DATE MAILED:
`
`Please find below and/or attached an Office communication concerning this application or
`proceeding.
`
`Called David Staple on Nov. 14, 2017 for approval to change the dependency of claim 9 to now depend on claim 8.
`
`Commissioner for Patents
`
`/JANA A HINES/
`Primary Examiner, Art Unit 1645
`
`PTO-90C (Rev.04-03)
`
`Genome Ex. 1014
`Page 4 of 1502
`
`

`

`Application/Control Number: 15/170,284
`Art Unit: 1645
`
`Page 2
`
`DETAILED CORRESPONDENCE
`
`Notice of Pre-AIA or AIA Status
`
`1.
`
`The present application, filed on or after March 16, 2013, is being examined
`
`under the first inventor to file provisions of the AIA.
`
`2.
`
`Claims 1-26 and 28-30 are under consideration in this Office Action.
`
`Claim Amendments
`
`EXAMINER'S AMENDMENT
`
`3.
`
`Authorization for this examiner's amendment was given in an interview with
`
`David Staple on November 14, 2017.
`
`The application has been amended as follows: The following is an examiner's
`
`statement of reasons for allowance:
`
`Claim 9. (Currently Amended) The method of claim S 8, wherein the
`
`administration of the two or more doses are separated by at least 1 week.
`
`4.
`
`Any comments considered necessary by applicant must be submitted no later
`
`than the payment of the issue fee and, to avoid processing delays, should preferably
`
`accompany the issue fee. Such submissions should be clearly labeled "Comments on
`
`Statement of Reasons for Allowance."
`
`Genome Ex. 1014
`Page 5 of 1502
`
`

`

`Application/Control Number: 15/170,284
`Art Unit: 1645
`
`Page 3
`
`Reasons for Allowance
`
`6.
`
`The following is an examiner's statement of reasons for allowance: The art does
`
`not teach or fairly suggest a method of treating cancer in a human subject comprising
`
`co-administering to the subject an immune checkpoint inhibitor and a bacterial
`
`formulation comprising bacteria of the genus Bifidobacterium.
`
`Any comments considered necessary by applicant must be submitted no later
`
`than the payment of the issue fee and, to avoid processing delays, should preferably
`
`accompany the issue fee. Such submissions should be clearly labeled "Comments on
`
`Statement of Reasons for Allowance."
`
`7.
`
`Claims 1-26 and 28-30 are allowed.
`
`Conclusion
`
`8.
`
`Any inquiry concerning this communication or earlier communications from the
`
`examiner should be directed to JA-NA A HINES whose telephone number is (571)272-
`
`0859. The examiner can normally be reached on M-Th 8:30am-6pm.
`
`Examiner interviews are available via telephone, in-person, and video
`
`conferencing using a USPTO supplied web-based collaboration tool. To schedule an
`
`interview, applicant is encouraged to use the USPTO Automated Interview Request
`
`(AIR) at http://www.uspto.gov/interviewpractice.
`
`Genome Ex. 1014
`Page 6 of 1502
`
`

`

`Application/Control Number: 15/170,284
`Art Unit: 1645
`
`Page 4
`
`If attempts to reach the examiner by telephone are unsuccessful, the examiner's
`
`supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for
`
`the organization where this application or proceeding is assigned is 571-273-8300.
`
`Information regarding the status of an application may be obtained from the
`
`Patent Application Information Retrieval (PAIR) system. Status information for
`
`published applications may be obtained from either Private PAIR or Public PAIR.
`
`Status information for unpublished applications is available through Private PAIR only.
`
`For more information about the PAIR system, see http://pair-direct.uspto.gov. Should
`
`you have questions on access to the Private PAIR system, contact the Electronic
`
`Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a
`
`USPTO Customer Service Representative or access to the automated information
`
`system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
`
`/JANA A HINES/
`Primary Examiner, Art Unit 1645
`
`Genome Ex. 1014
`Page 7 of 1502
`
`

`

`Examiner-Initiated Interview Summary
`
`Application No.
`
`15/170,284
`
`Examiner
`
`Applicant(s)
`
`Gajewski et al.
`
`Art Unit
`
`AIA Status
`
`JA-NA A HINES
`
`1645
`
`Yes
`
`All participants (applicant, applicant's representative, PTO personnel):
`
`(1) JA-NA A. HINES.
`
`(2) David Staple.
`
`(3)
`
`(4)
`
`Date of Interview: 14 November 2017.
`
`Type:
`
`0 Video Conference
`0 Telephonic
`D Personal [copy given to: 0 applicant D applicant's representative]
`CI No.
`
`Exhibit shown or demonstration conducted: 0 Yes
`If Yes, brief description:
`
`Issues Discussed 0 101 0 112 0 102 D 103 2 Others
`(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)
`
`Claim(s) discussed: 9.
`
`Identification of prior art discussed:
`
`.
`
`Substance of Interview
`(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference
`or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)
`
`Called David Staple on Nov. 14, 2017 for approval to change the dependency of claim 9 to now depend on claim 8..
`
`Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.
`
`Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the
`substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general
`thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or
`outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.
`
`0 Attachment
`
`/JANA A HINES/
`Primary Examiner, Art Unit 1645
`
`U.S. Patent and Trademark Office
`PTOL-413B (Rev. 8/11/2010)
`
`Interview Summary
`
`Paper No. 20171114
`
`Genome Ex. 1014
`Page 8 of 1502
`
`

`

`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`15/170,284
`
`06/01/2016
`
`Thomas F. Gajewski
`
`UCHI-34458/US-3/ORD
`
`8885
`
`72960
`7590
`11/09/2017
`Casimir Jones, S.C.
`2275 DEMING WAY, SUITE 310
`MIDDLETON, WI 53562
`
`EXAMINER
`
`HINES, JANA A
`
`ART UNIT
`
`1645
`
`PAPER NUMBER
`
`NOTIFICATION DATE
`
`DELIVERY MODE
`
`11/09/2017
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the
`following e-mail address(es):
`docketing@casimirjones.com
`pto.correspondence@casimirjones.com
`
`PTOL-90A (Rev. 04/07)
`
`Genome Ex. 1014
`Page 9 of 1502
`
`

`

`Response to Rule 312 Communication
`
`Application No.
`
`Applicant(s)
`
`15/170,284
`Examiner
`
`Art Unit
`
`-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address —
`
`1. 0 The amendment filed on 02 November 2017 under 37 CFR 1.312 has been considered, and has been:
`a) 0 entered.
`
`b) q entered as directed to matters of form not affecting the scope of the invention.
`
`c) q disapproved because the amendment was filed after the payment of the issue fee.
`Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and
`the required fee to withdraw the application from issue.
`
`d) q disapproved. See explanation below.
`
`e) q entered in part. See explanation below.
`
`Publishing Division
`
`mn
`
`U.S. Patent and Trademark Office
`PTOL-271 (Rev. 04-01)
`
`Reponse to Rule 312 Communication
`
`Part of Paper No.
`
`Genome Ex. 1014
`Page 10 of 1502
`
`

`

`Attorney Docket. No.: UCHI-34458/US-3/ORD
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Applicant:
`Serial No.:
`Filed:
`Title:
`
`8885
`Confirmation No.:
`University of Chicago
`1645
`Art Unit:
`15/170,284
`Hines, Jana A.
`01-JUNE-2016
`Examiner:
`TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL
`MICROFLORA
`
`RESPONSE TO NOTICE TO FILE CORRECTED
`APPLICATION PAPERS MAILED NOVEMBER 1, 2017
`After Notice of Allowance Mailed
`
`VIA EFS-WEB
`COMMISSIONER FOR PATENTS
`P.O. BOX 1450
`ALEXANDRIA, VA 22313-1450
`
`Examiner Hines:
`
`This communication is responsive the Notice to File Corrected Application Papers mailed
`
`November 1, 2017. Applicant requests that the amendments provided herein be entered under 37
`
`C.F.R. 1.312.
`
`The Commissioner is authorized by this paper to charge any fees during the entire
`
`pendency of this application, including fees due under 37 C.F.R. §§ 1.16 and 1.17 that may be
`
`required, including any required extension of time fees, or credit any overpayment to Deposit
`
`Account 50-4302, referencing Attorney Docket No.: UCHI-34458/US-3/ORD. This paragraph is
`
`intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance
`
`with 37 C.F.R. § 1.136(a)(3).
`
`Genome Ex. 1014
`Page 11 of 1502
`
`

`

`Attorney Docket. No.: UCHI-34458/US-3/ORD
`
`AMENDMENTS TO THE SPECIFICATION
`
`Please replace the paragraph beginning on page 9, lines 28-31, through page 10, lines 1-7,
`
`the following amended paragraph.
`
`-- Fig. 1A-[[H]]I. Differences in melanoma outgrowth and tumor-specific immune
`
`responses between C57BL/6 JAX and TAC mice are eliminated upon cohousing. (A) B16.SIY
`
`tumor growth kinetics in newly arrived JAX and TAC mice. (B) IFN-y ELISPOT in tumor-
`
`bearing JAX and TAC mice 7 days following tumor inoculation. (C) Mean size of IFN-y spots
`
`(10-3 mm2). (D) Flow cytometry of STY T cells from total CD8+ T cells within the tumor of JAX
`
`and TAC mice as determined by flow cytometry 21 days post-tumor inoculation. Percentage of
`
`ST-Y* T cells of total CDS* T cells within the tumor of JAX and TAC mice as determined by flow
`
`cytometry 21 days post tumor inoculation. Representative plots (left), quantification (right). (E)
`
`Percentage of STY+ T cells of total CD8+ T cells within the tumor of JAX and TAC mice as
`
`determined by flow cytometry 21 days post-tumor inoculation. ([[E]]F) B16.SIY tumor growth
`
`kinetics in JAX and TAC mice cohoused for 3 weeks prior to tumor inoculation. ([[F]]G)
`
`Number of IFN-y spots/106 splenocytes in tumor-bearing JAX and TAC mice cohoused for 3
`
`weeks prior to tumor inoculation. ([[G]]H) Mean size of IFN-y spots (10-3 mm2). ([[H]]I)
`
`Percentage of STY+ T cells of total CD8+ T cells within the tumor of JAX and TAC mice
`
`cohoused for 3 weeks prior to tumor inoculation.--
`
`2
`
`Genome Ex. 1014
`Page 12 of 1502
`
`

`

`Attorney Docket. No.: UCHI-34458/US-3/ORD
`
`AMENDMENTS TO THE FIGURES
`
`Please replace sheet 3 and 4 of the figures with the replacement sheet filed herewith.
`
`3
`
`Genome Ex. 1014
`Page 13 of 1502
`
`

`

`Attorney Docket. No.: UCHI-34458/US-3/ORD
`
`REMARKS
`
`In the Notice to File Corrected Application Papers mailed November 1, 2017, the
`
`Applicant was notified that the FIG. 1D continued onto a second page without proper labeling.
`
`The Applicant files herewith a replacement sheet of the second page of FIG. 1D now relabeled
`
`FIG. 1E in compliance with 37 C.F.R. 1.84(u)(1). Additionally, the Applicant submits herewith
`
`a replacement sheet of page 4 of the figures with FIGS. 1E-H relabeled FIGS. 1F-I. No new
`
`matter is added.
`
`The Applicant has also amended the Brief Description of the Drawings to include
`
`reference to relabeled figures and amended the figures descriptions for Figures 1D and 1E. No
`
`new matter is added by this amendment.
`
`CONCLUSION
`
`Applicant respectfully submits that the remarks herein overcome the Office's rejections
`
`and place the claims in condition for allowance. If the Examiner wishes to discuss this case,
`
`Applicants encourage the Examiner to call the undersigned at 608-662-1277 at the Examiner's
`
`convenience.
`
`Respectfully submitted,
`
`Date: November 2, 2017
`
`/David W. Staple/
`
`David W. Staple
`Registration No. 65,903
`Casimir Jones S.C.
`2275 Deming Way
`Suite 310
`Middleton, WI 53562
`Tel.: 608-662-1277
`Fax.: 608-662-1276
`
`4
`
`Genome Ex. 1014
`Page 14 of 1502
`
`

`

`REPLACEMENT SHEET
`
`FIG. lE
`
`+
`03
`
`•
`
`A
`A
`a
`
`TAG
`
`JAX
`
`Genome Ex. 1014
`Page 15 of 1502
`
`

`

`Gated on CD8
`
`TAC
`-6- JAX
`
`NS
`
`150
`
`ce7-7—
`E
`E
`ro 100
`E
`
`50
`
`E
`
`REPLACEMENT SHEET
`
`NS
`
`4
`
`40
`
`a 30
`
`200
`
`En
`5; 10
`z*
`
`•
`
`•
`• •
`• • •
`
`•
`• ••• •
`•
`S
`
`7 10 13 16 .20 22
`Day post injection
`
`TAC
`
`JAX
`
`FIG. 1F
`
`FIG. 1G
`
`50
`
`I
`
`NS
`
`E
`E 40
`C
`
`30
`
`CD
`*ZT) 20
`
`o cici) 10
`
`2
`
`0
`
`NS
`
`A
`
`40
`
`30
`
`20
`
`co
`
`0
`5- 10
`Ci)
`0
`
`JAX
`TAC
`FIG. 1H
`
`TAC
`FIG. 1I
`
`AX
`
`4/46
`
`Genome Ex. 1014
`Page 16 of 1502
`
`

`

`Electronic Acknowledgement Receipt
`
`EFS ID:
`
`Application Number:
`
`30834653
`
`15170284
`
`International Application Number:
`
`Confirmation Number:
`
`8885
`
`Title of Invention:
`
`TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA
`
`First Named Inventor/Applicant Name:
`
`Thomas F. Gajewski
`
`Customer Number:
`
`72960
`
`Filer:
`
`David William Staple/Stephanie Filandrinos
`
`Filer Authorized By:
`
`David William Staple
`
`Attorney Docket Number:
`
`UCHI-34458/US-3/ORD
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`02-NOV-2017
`
`01-JUN-2016
`
`16:13:28
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`Payment information:
`
`Submitted with Payment
`
`no
`
`File Listing:
`
`Document
`Number
`
`1
`
`Document Description
`
`File Name
`
`File Size(Bytes)/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(if appl.)
`
`115257
`
`34458US3ORD_RNCAP_11-2-1
`7.pdf
`
`0623e905f89ac31ca4cbf00204d76ce66866
`fd8a
`
`yes
`
`4
`
`Genome Ex. 1014
`Page 17 of 1502
`
`

`

`Multipart Description/PDF files in .zip description
`
`Document Description
`
`Start
`
`End
`
`Amendment after Notice of Allowance (Rule 312)
`
`Specification
`
`Drawings-only black and white line drawings
`
`Applicant Arguments/Remarks Made in an Amendment
`
`1
`
`2
`
`3
`
`4
`
`1
`
`2
`
`3
`
`4
`
`Warnings:
`
`Information:
`
`2
`
`Drawings-only black and white line
`drawings
`
`34458-ORD-REPLACEMENT-
`FIGURES1 E-I.pdf
`
`337236
`
`fad54ee970c6c4a2ea93f28b3a71546bbb9
`d356b
`
`no
`
`2
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes):
`
`452493
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`
`
`
`
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`includes the necessary components If a new application is being filed and the application for a filing date (see 37 CFR
`
`
`
`1.54) will be issued in due 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR course and the date shown on this
`
`
`date of the application. Acknowledgement Receipt will establish the filing
`35 U.S.C. 371 National Stage of an International Application under
`
`
`is compliant with the conditions of 35 If a timely submission to enter the national stage of an international application
`
`acceptance of the application as a U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating
`
`Filing Receipt, in due course. national stage submission under 35 U.S.C. 371 will be issued in addition to the
`New International Application Filed with the USPTO as a Receiving Office
`includes the necessary components for If a new international application is being filed and the international application
`
`
`of the International Application Number an international filing date (see PCT Article 11 and MPEP 1810), a Notification
`subject to prescriptions concerning and of the International Filing Date (Form PCT/RO/105) will be issued in due course,
`
`
`establish the international filing date of national security, and the date shown on this Acknowledgement Receipt will
`the application.
`
`Genome Ex. 1014
`Page 18 of 1502
`
`

`

`Doc Code: IFEE
`
`PTOL/85 B-EFS
`
`Document Description: Issue Fee Payment (PTO-85B)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`
`Atty. Docket No.
`
`Confirmation No.
`
`Issue Fee Transmittal Form
`
`15170284
`
`01-Jun-2016
`
`Thomas Gajewski
`
`UCHI-34458/US-3/ORD
`
`8885
`
`TITLE OF INVENTION :
`
`TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA
`
`Entity Status
`
`Application Type
`
`Art Unit Class - Subclass
`
`EXAMINER
`
`Small
`
`Utility under 35 USC 111(a)
`
`1645
`
`007320
`
`JANA HINES
`
`Issue Fee Due
`
`Publication Due
`
`Total Fee(s) Due
`
`Date Due
`
`Prey. Paid Fee
`
`$480
`
`$0
`
`$480
`
`29-Dec-2017
`
`$0
`
`1.Change of Correspondence Address and/or Indication Of Fee Address (37 CFR 1.33 & 1.363)
`Current Correspondence Address:
`Current Indicated Fee Address :
`
`72960
`Casimir Jones, S.C.
`
`2275 DEMING WAY, SUITE 310
`
`MIDDLETON WI 53562
`UNITED STATES
`608-662-1277
`docketing@casimirjones.com
`1--1 Change of correspondence address requested, system
`I—I generated AIA/122-EFS form attached
`
`2.Entity Status
`
`Change in Entity Status
`
`1--1 Fee Address indication requested, system generated SB/47-EFS
`"
`form attached
`
`Applicant certifying micro entity status; system generated Micro Entity certification form attached. See 37 CFR 1.29.
`Note: Absent a valid certification of micro entity status, issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
`If this box is checked, you will be prompted to choose a micro entity status on the gross income basis (37 CFR 1.29(a)) or the institution of higher education basis
`(37 CFR 1.29(d)), and make the applicable certification online.
`
`O
`
`Applicant asserting small entity status. See 37 CFR 1.27.
`Note: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
`
`O
`
`Applicant changing to regular undiscounted fee status.
`Note: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.
`
`WEB IEEE 1.0
`
`Genome Ex. 1014
`Page 19 of 1502
`
`

`

`PTOL/85B-EFS
`
`n I authorize USPTO to apply my previously paid issue fee to the
`
`
`
` current fees due
`
`The Director is hereby authorized to apply my previously paid
`
`n issue fee to the current fee due and to charge deficient fees to
`
`Deposit Account Number
`
`
`
`If in addition to the payment of the issue fee amount submitted
`with this form, there are any discrepancies in any amount(s) due,
`the Director is authorized to charge any defcArib or credit any
`overpayment, to Deposit Account Number
`The issue fee must be submitted with this form. If payment of
`the issue fee does not accompany this form, checking this box
`and providing a deposit account number will NOT be
`effective to satisfy full payment of the fee(s) due.
`
`Doc Code: IFEE
`
`Document Description: Issue Fee Payment (PTO-85B)
`
`3.The Following Fee(s) Are Submitted:
`
`Z
`
`Issue Fee
`
`n Publication Fee
`
`n Advance Order - # of copies
`
`
`
`4.Firm and/or Attorney Names To Be Printed
`NOTE: If no name is listed, no name will be printed
`For printing on the patent front page, list to be displayed as entered
`
`1. CASIMIR JONES SC
`
`2. David W. Staple
`
`3.
`
`5.Assignee Name(s) and Residence Data To Be Printed
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`
`Name
`
`City
`
`State
`
`Country
`
`Category
`
`The University of Chicago
`
`Chicago
`
`ILLINOIS
`
`united states
`
`other
`
`6.Signature
`
`I certify, in accordance with 37 CFR 1.4(d)(4) that I am an attorney or agent registered to practice before the Patent and Trademark Office who has filed and has been granted
`power of attorney in this application. I also certify that this Fee(s) Transmittal form is being transmitted to the USPTO via EFS-WEB on the date indicated below.
`
`Signature
`
`/David W. Staple/
`
`Date
`
`11-02-2017
`
`Name
`
`David William Staple
`
`Registration Number 65903
`
`WEB IEEE 1.0
`
`Genome Ex. 1014
`Page 20 of 1502
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`15170284
`
`01-Jun-2016
`
`Title of Invention:
`
`TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA
`
`First Named Inventor/Applicant Name:
`
`Thomas F. Gajewski
`
`Filer:
`
`David William Staple/Stephanie Filandrinos
`
`Attorney Docket Number:
`
`UCHI-34458/US-3/ORD
`
`Filed as Small Entity
`
`Filing Fees for Utility under 35 USC 111(a)
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Basic Filing:
`
`UTILITY APPL ISSUE FEE
`
`PUBL. FEE- EARLY, VOLUNTARY, OR NORMAL
`
`2501
`
`1504
`
`1
`
`1
`
`480
`
`0
`
`480
`
`0
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-Interference:
`
`Genome Ex. 1014
`Page 21 of 1502
`
`

`

`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Post-Allowance-and-Post-Issuance:
`
`Extension-of-Time:
`
`Miscellaneous:
`
`Total in USD ($)
`
`480
`
`Genome Ex. 1014
`Page 22 of 1502
`
`

`

`Electronic Acknowledgement Receipt
`
`EFS ID:
`
`Application Number:
`
`30834693
`
`15170284
`
`International Application Number:
`
`Confirmation Number:
`
`8885
`
`Title of Invention:
`
`TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA
`
`First Named Inventor/Applicant Name:
`
`Thomas F. Gajewski
`
`Customer Number:
`
`72960
`
`Filer:
`
`David William Staple/Stephanie Filandrinos
`
`Filer Authorized By:
`
`David William Staple
`
`Attorney Docket Number:
`
`UCHI-34458/US-3/ORD
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`02-NOV-2017
`
`01-JUN-2016
`
`16:14:35
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`yes
`
`CARD
`
`$480
`
`RAM confirmation Number
`
`110317INTEFSW16143400
`
`Deposit Account
`
`Authorized User
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Genome Ex. 1014
`Page 23 of 1502
`
`

`

`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Name
`
`File Size(Bytes)/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(if appl.)
`
`46162
`
`1
`
`Issue Fee Payment (PTO-85B)
`
`Web85b.pdf
`
`no
`
`2
`
`Warnings:
`
`Information:
`
`9466911e41112c065d5091Medc96e56603
`8b49
`
`32421
`
`2
`
`Fee Worksheet (SI306)
`
`fee-info.pdf
`
`no
`
`2
`
`9258dd58908c45563b4144323d3687eaae
`89013d
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes):
`
`78583
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`
`
`
`
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`includes the necessary components If a new application is being filed and the application for a filing date (see 37 CFR
`
`
`
`1.54) will be issued in due 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR course and the date shown on this
`
`
`date of the application. Acknowledgement Receipt will establish the filing
`35 U.S.C. 371 National Stage of an International Application under
`
`
`is compliant with the conditions of 35 If a timely submission to enter the national stage of an international application
`
`acceptance of the application as a U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating
`
`Filing Receipt, in due course. national stage submission under 35 U.S.C. 371 will be issued in addition to the
`New International Application Filed with the USPTO as a Receiving Office
`includes the necessary components for If a new international application is being filed and the international application
`
`
`of the International Application Number an international filing date (see PCT Article 11 and MPEP 1810), a Notification
`subject to prescriptions concerning and of the International Filing Date (Form PCT/RO/105) will be issued in due course,
`
`
`establish the international filing date of national security, and the date shown on this Acknowledgement Receipt will
`the application.
`
`Genome Ex. 1014
`Page 24 of 1502
`
`

`

`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`15/170,284
`
`06/01/2016
`
`Thomas F. Gajewski
`
`UCHI-34458/US-3/ORD
`
`8885
`
`7590
`72960
`Casimir Jones, S.C.
`2275 DEMING WAY, SUITE 310
`MIDDLETON, WI 53562
`
`11/01/2017
`
`EXAMINER
`
`HINES, JANA A
`
`ART UNIT
`
`PAPER NUMBER
`
`1645
`
`NOTIFICATION DATE
`
`DELIVERY MODE
`
`11/01/2017
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the
`following e-mail address(es):
`docketing@casimirjones.com
`pto.correspondence@casimirjones.com
`
`PTOL-90A (Rev. 04/07)
`
`Genome Ex. 1014
`Page 25 of 1502
`
`

`

`0.c" UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Commissioner for Patents